-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Author: Shi Bei
On December 8, AstraZeneca announced that the FDA had approved an emergency use authorization application for its long-acting antibody cocktail therapy Evusheld (tixagevimab+cilgavimab) for the prevention of SARS-CoV-2 before exposure
Evusheld is a combination of two long-acting antibodies, tixagevimab and cilgavimab
In August 2021, AstraZeneca announced the positive results of the pre-exposure prevention PROVENT study.
Evusheld also has the potential to provide a treatment and prevent disease progression for patients who have been infected with the SARS-CoV-2 virus
On October 11, AstraZeneca announced that the long-acting antibody (LAAB) cocktail therapy AZD7442 has achieved positive and high-level results in the Phase III TACKLE trial for the treatment of COVID-19
The trial reached its primary endpoint
In a pre-specified analysis of subjects who received treatment within 5 days of the onset of symptoms, AZD7442 reduced the risk of progression to severe COVID-19 or death (for any reason) by 67% compared with placebo.
Compared with placebo, AZD7442 significantly reduced the risk of severe COVID-19 or death among non-hospitalized COVID-19 patients with mild to moderate symptoms
